Spire Wealth Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Spire Wealth Management’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-142	Closed	-$1K	–	2666
2022 Q2	$1K	Buy	+142	New	+$404	﹤0.01%	2611
2022 Q1	–	Sell	-1,427	Closed	-$5K	–	2939
2021 Q4	$5K	Sell	1,427 -2,271	-61%	-$12.1K	﹤0.01%	2587
2021 Q3	$30K	Sell	3,698 -3,425	-48%	-$33.8K	﹤0.01%	1697
2021 Q2	$81K	Buy	7,123 +4,902	+221%	+$49.2K	﹤0.01%	1280
2021 Q1	$21K	Buy	+2,221	New	+$23.1K	﹤0.01%	2137

Other funds holding VIRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Spire Wealth Management's VIRX Position: Q3 2022 in Review

Spire Wealth Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2022, closing a stake of 142 shares — an estimated $1K sold.

Spire Wealth Management first reported a position in VIRX in Q1 2021 and held it in 5 quarters. The position peaked at $81K in Q2 2021. 59 funds tracked by Wall St. Rank hold VIRX as of Q3 2022.

Spire Wealth Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Spire Wealth Management sold 142 Viracta Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $1K.
Spire Wealth Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
Spire Wealth Management's Viracta Therapeutics, Inc. Common Stock position peaked at $81K in Q2 2021.
59 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Spire Wealth Management's 13F filing for Q3 2022, filed 7 Nov 2022.